At Cortado Ventures, we back entrepreneurs that are inventing the future, and we are thrilled about our investment in Moat Biotechnology. Moat’s technology is based on a next-generation adenovirus platform from the Mayo Clinic. Our General Partner Mike Moradi articulates our commitment to Moat Biotechnology, the first western company to demonstrate a successful inhaled COVID booster in a human clinical trial. Read More.
- GeoMark Research and Senslytics Forge Strategic Partnership to Pioneer Breakthroughs in Artificial Intelligence Solutions
- Nathaniel Harding featured on podcasts
- Cortado Ventures Doubleshot Newsletter: November 2023
- MidCon Markup Ep. 3: How to Raise Venture Capital with Susan Moring
- nSight Surgical Honored with Surgical Transformation award